Quick Answer
Apimeds Pharmaceuticals US, Inc. reported Operating Income of -$1.28 million for fiscal year 2024.
Apimeds Pharmaceuticals US, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2024 | -$1.28M | -70.6% |
| 2023 | -$747.4K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.84M | -514.7% | +30.8% |
| June 30, 2025 | -$2.66M | -522.8% | -631.1% |
| March 31, 2025 | -$364.4K | -34.1% | -21.5% |
| September 30, 2024 | -$300.0K | — | +29.9% |
| June 30, 2024 | -$427.8K | — | -57.4% |
| March 31, 2024 | -$271.7K | — | — |
- Apimeds Pharmaceuticals US, Inc. showed a decrease of -70.6% in Operating Income compared to the prior fiscal year.
- Over the 2023–2024 period, Apimeds Pharmaceuticals US, Inc.’s operating income has declined by 70.6% (from -$747.4 thousand to -$1.28 million).
- The most recent figure is from Apimeds Pharmaceuticals US, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: